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Over the past decade, there has been increasing interest in the use of multifunctional 
nanoparticles (NPs) for cancer treatment. Of importance are systems that can deliver drugs at a 
sustained rate to target cancer cells, which can result in higher efficiency and reduced systemic 
toxicity. In this study, we present the route for the synthesis of tantalum pentoxide (Ta2O5) NPs 
with a particle size of 27 nm that were individually coated with poly(acrylic acid) (PAA) with a 
different layer thickness of 2 – 8 nm by in-situ polymerization of the acrylic acid monomer. The 
capability of Ta2O5-PAA to provide anatomical contrast-enhancing features has been 
demonstrated via computed tomography. The Ta2O5-PAA conjugate was further loaded with 
methotrexate, and the drug release was observed for a total of 72 h at a pH of 3.6, 5.4, 7.4, and 
9.4. While the different layer thicknesses did not influence the drug release kinetics, a decrease 
in pH of the release medium resulted in a slower drug release. The developed nanocomposite 
particles present a great potential as a theranostic system for biomedical applications. 
 
INTRODUCTION 
At present, cancer is still one of the leading causes of death worldwide. While classical cancer 
therapies such as surgery, chemotherapy, and radiation therapy are typically based on the 
removal of malignant tissue, new approaches try to improve anticancer treatments by combining 
multiple features on a single platform [1, 2]. These so-called theranostic systems consist of 
therapeutic, targeting, and diagnostic agents, which can also act as radiation-dose enhancing 
agents that can reduce the overall radiation dosage [3]. In particular, the use of nanoparticles 
(NPs) is of interest, since they navigate easily across various biological barriers to preferentially 
accumulate in tumor tissues due to their enhanced permeability and retention effects [4]. 
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Ta2O5 is a transition metal oxide that can be synthesized by precipitation routes with subsequent 
annealing [5]. Furthermore, Ta2O5 is chemically inert [6], biocompatible [7], shows good 
radiopacity [8], and is nearly insoluble, except for very strong bases and hydrofluoric acid [9, 
10]. Due to the high atomic number of Ta (Z = 73) and density of 16.6 g/cm3, Ta2O5 NPs have 
been investigated for their ability to increase anatomical contrast [6, 11, 12], as well as the 
induction of dose enhancement on radioresistant 9L rat gliosarcoma cancer cells in an 
megavoltage (MV) photon field [5]. In vitro studies showed that at equal molar concentrations of 
tantalum and iodine, the image contrast was larger with tantalum across the diagnostic X-ray 
spectrum [6]. Another advantage of the use of NPs, and in particular Ta2O5 ones, is their facile 
modifiable surface and capability of loading with anti-cancer drugs, which is typically achieved 
with conjugation or encapsulation by a polymer layer [13]. These core-shell structures can 
further be of benefit for computed tomography (CT) imaging as they can be administrated 
intravenously and display subsequent renal clearance [6, 14]. 
The study of polymers for personalized medicine has been of increasing interest. On the 
nanoscale, polymers can improve the half-life, solubility, and stability of drug delivery systems, 
while reducing potential unpleasant chemotherapeutic side effects [15-17]. 
Poly(acrylic acid) (PAA) is a bio-adhesive polymer and does not require further treatment after 
insertion into the body [18, 19]. PAA is a biocompatible hydrophilic polymer that is a common 
component of hydrogels and can retain large amounts of water in its three-dimensional network 
[18]. Moreover, the shrinking and expansion of PAA depend on the pH value: an alkaline 




Common chemotherapeutic drugs that can be attached to the NPs include doxorubicin (DOX), 5-
fluorouracil (5-FU), and methotrexate (MTX). It was reported that mesoporous silica 
nanoparticles functionalized with polyethylene glycol succinate [21] or glycoprotein small 
interfering and a polydopamine outer layer [22] loaded with DOX showed to have a pH-sensitive 
release. The DOX molecules behave as pH and thermal responsive due to the pH-cleavage DOX 
gatekeeper in the mesoporous silica nanocore.  
MTX is an antineoplastic agent used not only in cancer treatment (breast, leukemia, lymphoma, 
lung, osteosarcoma and bladder neoplasms) but also for autoimmune disorders such as 
rheumatoid arthritis and ectopic pregnancies [23]. Furthermore, MTX possesses a higher affinity 
to dihydrofolate reductase (DHFR) than folates, binding competitively to DHFR to inhibit DNA, 
RNA, and protein synthesis inside malignant cells. Since cancer cells characteristically have an 
overexpression of folate receptors on their surfaces, MTX can potentially offer a targeting 
feature [23-25].  
In the clinical applications, high doses of MTX are often used (≥ 500 mg/m2) and administered 
intravenously in cycles within a single day, which is extremely painful for the patient. Hence, the 
development of controllable drug release delivery systems is required, to not only reduce the dosage 
frequency but also to decrease systemic toxicity [26], improving the patient overall life quality.  
In general, there are two methods to load hydrogels as drug carriers. In the first method, the drug is 
added to the monomer mixture during the polymerization, which allows trapping of the drug within 
the polymer matrix. Since the conditions for the polymerization may have deleterious effects on the 
drug properties, this method is not always favored [27]. In the second approach, the hydrogel is placed 
in a solution containing the drug and allowed to swell until equilibrium is reached [27-30]. 
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This work shows a route that uses the high surface area available in individual Ta2O5 
nanoparticles to polymerize a nanometric layer of PAA, by applying different polymerization 
times ranging from 1 – 5 h. The evolution of the polymer layer with the polymerization time was 
assessed and further correlated with the loading capacity of MTX that was measured by swelling 
of the hydrogel in the drug solution at pH 7.4. The drug release of MTX was studied at different 
pH values, ranging from 3.6 up to 9.4 for a total of 72 h, and the released kinetics were 
systematically studied. The method thus developed opens a new approach to create novel 
theranostic system for advanced cancer therapy treatments.   
 
MATERIALS AND METHODS  
Synthesis of Ta2O5 NPs: The tantalum pentoxide NPs were synthesized using a classical 
precipitation route. First, 10 g (24.62 mmol) of tantalum ethoxide (≥ 99.98%, Sigma-Aldrich) 
was transferred carefully with the exclusion of water into 200 mL of ethanol (≥ 99.8%, Sigma-
Aldrich). The solution was stirred at room temperature, and then 60 mL of deionized water was 
added quickly to the reaction mixture, which resulted in the formation of a white precipitate. The 
precipitate was filtered via centrifugation (Eppendorf), washed twice with deionized water, and 
dried at 90 °C overnight. To obtain crystalline Ta2O5, the precipitate was annealed in a tube 
furnace (LABEC) at 730 °C for 30 minutes under atmospheric conditions. 
Coating of Ta2O5 NPs with PAA: The coating of Ta2O5 NPs with PAA was performed in three 
steps. First, 330 mg of Ta2O5 NPs was added into a centrifuge tube containing 25 mL of 
methanol (≥ 99.8%, Sigma-Aldrich). The centrifuge tube was placed in a sonication bath 
(Branson 3800, Ultrasonics Corp) and sonicated for 25 min. Then, the suspension was 
centrifuged, the NPs were resuspended in 20 mL of concentrated hydrochloric acid (37%, 
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Sigma-Aldrich), and the suspension was stirred gently under nitrogen (N2) flow for 25 min. The 
suspension was centrifuged, and the NPs were resuspended in 20 mL of AA (99%, Sigma-
Aldrich) and placed back under N2-flow. The suspension was stirred for a total of 1, 2.5, and 5 h, 
respectively, at a temperature of 80 ± 1°C. After the desired amount of time, 10 mL of 
chloroform (≥ 99%, Sigma-Aldrich) was added to the reaction mixture to stop the polymerization 
process. The suspension was then centrifuged, washed three times with chloroform, and the 
coated NPs were dried at room temperature for 48 h.  
To determine the surface properties of the Ta2O5 after treatment with HCl, an aliquot was taken 
before the resuspension in AA, washed three times with methanol, and dried at room temperature 
for 48 h. 
Materials Characterization: The crystalline state of the materials was investigated using an 
Enhanced Mini-Materials Analyzer (EMMA) X-Ray Diffractometer from GBC Scientific. The 
measurements were carried out at room temperature with Cu Kα radiation (λ = 1.5418 Å) at 40 
kV and 25 mA in the range of 20 to 80° at a rate of 2.00°/min with a step size of 0.02°. The mean 




    (1) 
where d, K, λ, β, and θ is the average crystallite size, a constant (K = 0.89 for spherical particles), 
the wavelength of the X-ray radiation, the full width at half maximum, and the Bragg angle of 
diffraction, respectively.  
Particle sizes and core-shell structures of the uncoated and coated samples were examined using 
a JEOL 7500 field emission scanning electron microscope (FESEM) and a JEOL JEM-2010 
transmission electron microscope (TEM). A suspension of 0.5 mg/mL of the NPs in 2-propanol 
(≥ 99.5%, Sigma-Aldrich) was prepared and sonicated for 30 min, and one droplet was placed on 
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an LC 200-CU lacey/carbon 200 mesh copper grid. To acquire SEM images, an accelerating 
voltage of 5 kV with a working distance of 10 mm and a spot size of 10 was used. TEM images 
were acquired at an accelerating voltage of 200 kV.  
Fourier-transform infrared spectroscopy (FTIR) was recorded on an IR Prestige 21 spectrometer 
(Shimadzu) between 4000 to 600 cm-1 via attenuated total reflectance ATR) using the MIRacle 
attachment and the number of scans was fixed to 64 with a resolution of 4 cm-1. 
The surface composition of Ta2O5 NPs, both after their treatment with HCl and after 
polymerization with AA was evaluated via XPS using a SPECS PHOIBOS 100 Analyzer 
installed in a high vacuum chamber with base pressure below 10−8 mbar. X-ray excitation was 
provided by Al Kα radiation with a photon energy of 1486.6 eV at a voltage of 12 kV and power 
of 120 W. The XPS binding energy spectra were recorded with a pass energy of 20 eV in fixed 
analyzer transmission mode, and the data analysis was carried out using CasaXPS v2.3.15 
software.  
The stability of the Ta2O5-PAA NPs was determined via TGA using a Mettler Toledo TGA/DSC 
1 STAR-e system. Each sample was placed in an aluminum oxide pan and heated from 50 – 
800°C at a heating rate of 5°C/min under air atmosphere. 
Computed Tomography: The anatomical contrast enhancement capabilities of Ta2O5 NPs and the 
Ta2O5-PAA nanocomposite synthesized with the highest polymerization time was demonstrated 
using CT. Suspensions with concentrations of Ta ranging from 0 to 8 mg/mL in PBS were 
prepared in 1.5 mL vials and sonicated for 2 h. Then, the vials were imaged together using a 
Toshiba Asteion (model TSX-021A) whole body X-ray CT scanner with a tube voltage of 100, 
120, and 135 kV. The CT images were obtained using the standard patient image reconstruction 
algorithms included with the scanner. 
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Swelling Studies: The swelling studies were conducted in buffer solutions with a pH of 3.6, 5.4, 
7.4, and 9.4 at 37 ᵒC. First, the weighted mass of the dry Ta2O5-PAA NPs (W0) was added into 
the buffer solution with the desired pH value. At predetermined time intervals, the NPs were 
removed from the swelling medium, blotted with filter paper to remove excess buffer solution 
from the NP surfaces, and the weight of the swollen composite (W1) was determined. The 
swelling behavior of the composites was observed for a total of 48 h, and the swelling ratio (SR) 





  (2) 
In Vitro Drug Loading: For each polymerization time, a sample mass of 200 mg of Ta2O5-PAA 
NPs was added to 20 mL of a solution of 10 mg/mL MTX (≥ 98%, Sigma-Aldrich) in PBS. The 
soaked NPs were rinsed with PBS and dried under vacuum until the weight remained constant. 
The loading capacity was calculated according to: 
 
Loading	capacity	(%) =
 !	"!#$ %	&	% !	!'%()**!+	+(,$
 !	"!#$ %	&	+(-	.*#%!
∗ 100           (3) 
 
The entrapment efficiency was determined by:  
 
Entrapment	efficiency	(%) =
 !	"!#$ %	&	% !	!'%()**!+	+(,$
 !	"!#$ %	&	+(,$	,!+	&(	!'%()*.!'%
∗ 100        (4) 
 
In Vitro Drug Release Studies: To study the release profiles for the MTX-loaded Ta2O5-PAA 
NPs, 10 mg of the dry MTX-loaded NPs was added into glass vials, to which 10 mL of release 
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medium (buffer) was added. The release medium varied in pH value (pH: 3.6, 5.4, 7.4, and 9.4). 
The vials were placed on an orbital shaker at a rotation rate of 50 rpm and a constant temperature 
of 37 ± 1 °C. After predetermined time intervals (0, 15, 30, 45 min, and 1, 2, 6, 12, 24, and 72 h), 
5 mL aliquots were taken for further quantification. UV-vis spectroscopy was used to determine 
the concentration of MTX present in the supernatant at a wavelength of 303 nm [31]. The 
absorbance was recorded on a UV-3600 spectrophotometer from Shimadzu over the range of 800 
to 200 nm by using quartz cuvettes (optical path of 10 mm).  
The concentration of MTX was determined by the Beer-Lambert law, and a calibration curve 
was established with known concentrations of MTX solutions: 
7 = 89:   (5) 
where A is the absorbance, c is the concentration of the compound in solution, ε is the extinction 
coefficient, and l is the path length of the sample. The total amount of soaked MTX was 
estimated by centrifugation of the 72 h sample at 5000 rpm for 10 min. The remaining pellet was 
suspended in 0.1 M sodium hydroxide (NaOH, Sigma-Aldrich), as MTX is highly soluble in 0.1 
M NaOH, and sonicated for 1 h. Then, methanol (Sigma-Aldrich) was added to the solution, 
which was sonicated for an additional 1 h [31].  
 
RESULTS AND DISCUSSION 
Nanocomposite particles crystallinity and morphology: X-Ray diffraction (XRD) was used to 
determine the crystalline phase of the Ta2O5 NPs before and after PAA polymerization onto the 
surface of the NPs. The obtained diffraction patterns (Figure 1a) show the presence of a single δ 
hexagonal phase with a crystallite size (calculated through the Scherrer equation) of 26.7 ± 5.4 
10 
 
nm, with all reflections matching the JCPDS card no. 19-1299. Furthermore, the coating of 






Figure 1. a) XRD patterns of Ta2O5 NPs and Ta2O5-PAA nanocomposites with polymerization 
times of 1, 2.5, and 5 h, b) Particle size distribution of uncoated Ta2O5 NPs (a total of 100 
particles were measured, and the relative frequency was plotted as a function of particle size), c) 
The plot of the layer thickness as a function of the polymerization time, d) SEM and e) TEM 
images of Ta2O5 NPs and Ta2O5-PAA nanocomposites with polymerization times of 1, 2.5, and 5 
h. The green arrows indicate the PAA layers, and f) The expected reaction for the as-prepared 
Ta2O5 nanoparticles when dispersed in methanol (left) and etched with hydrochloric acid for 25 
min. After centrifugation, the hydroxyl-terminated nanoparticles were transferred into an acrylic 
acid solution (center) and heated up to 80 ± 1 °C for different polymerization times.      
 
In general, pristine Ta2O5 and Ta2O5-PAA NPs are mostly spherical and ellipsoidal in shape and 
tend to form agglomerates with > 100 nm in size, which is observed for both Ta2O5 and Ta2O5-
PAA and is probably due to their high surface energy [32]. The single particle size of the 
uncoated Ta2O5 NPs varies between 13 – 57 nm with an average particle size of 26.6 ± 5.9 nm 
(Figure 1b). These findings agree with the mean crystallite size calculated via the Scherrer 
equation and indicate that the Ta2O5 NPs are an excellent candidate for the design of theranostic 
systems since it has been shown that a particle size of up to 50 nm results in high cellular uptake 
[33]. 
The TEM images of the Ta2O5-PAA nanocomposites show homogeneous coverage of the 
surfaces of individual Ta2O5 NPs with layers of PAA. It is also demonstrated that the PAA layer 
thickness increases with increasing polymerization time: while polymerization for 1 h yields a 
polymer thickness of 2.1 ± 0.7 nm, a polymerization time of 2.5 and 5 h leads to a thickness of 
3.9 ± 0.9 nm and 8.2 ± 1.4 nm, respectively.  
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The polymerization of the acrylic acid (AA) around individual particles is only possible if the 
surface Ta2O5 NPs are activated to induce preferential polymerization sites for the AA monomer, 
ensuring that the polymer chains grow around each individual ceramic particle, avoiding cluster 
formation Ta2O5 (Figures 1c and 1f) [34, 35]. Layer thickness is associated with the amount of 
drug that can be uptake and influences its release properties.  
 
Chemical and thermal properties of the Ta2O5 NPs and Ta2O5-PAA NPs: The FTIR spectrum of 
uncoated Ta2O5 NPs with presents bands at around 880 and 680 cm
-1 assigned to the Ta-O-Ta 
bridge and stretching vibrations of Ta-O bonds (Figure 2a), respectively [36]. 
The FTIR spectra of the Ta2O5-PAA nanocomposites show the presence of Ta-O and Ta-O-Ta 
vibrations in low wavenumbers < 900 cm-1, which overlap with the polymer stretching and 
bending vibrations. The characteristic O-H out-of-plane bending, and CH2 and C-COOH 
stretching are observed at 914 and 797 cm-1, respectively [37]. Besides these bands, all other 
characteristic absorption bands that correspond to PAA are present in the Ta2O5-PAA 
nanocomposites: the absorption bands at 2946, 1451, and 1108 cm-1 correspond to CH2 or CH 
stretching, CH2 stretching, and C-CH2 stretching, respectively [37, 38]. In addition, the 
absorption bands at 1704 and 1240 cm-1 are ascribed to the C-O stretching and C=O stretching, 
respectively [37]. It was interesting to observe that the vibration band with a maximum at 1704 
cm-1 increased with the polymerization time. 
The monomer AA typically shows absorption bands at 1600 – 1680 cm-1, which are assigned to 
C=C stretching [39]. The absence of these absorption bands in the FTIR spectra of the Ta2O5-
PAA nanocomposites suggests the presence of polymer chains around the Ta2O5 nanoparticles. 
The increase in polymerization time generally leads to an increase in the intensity of the 
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absorption bands of the PAA characteristic functional groups, without changing their 
wavenumber.  
Figure 2. a) FTIR spectra of Ta2O5 NPs and Ta2O5-PAA nanocomposites with a polymerization 
time of 1, 2.5, and 5 h. The dotted line indicates the wavenumber, below which the absorption 
bands of Ta2O5 outweigh the absorption bands related to PAA, b) TGA curves of Ta2O5 NPs and 
Ta2O5-PAA nanocomposites with a polymerization time of 1, 2.5, and 5 h, c) First derivative of 
the TGA curve of Ta2O5-PAA with 5 h polymerization time, and d) Plot of the content of the 
organics as a function of the polymerization time. 
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Uncoated Ta2O5 NPs did not show any mass loss for the entire temperature scan range, while the 
Ta2O5-PAA nanocomposite materials exhibited characteristic mass losses that were due to the 
presence of the polymer on their surfaces (Figure 2b). Furthermore, a mass loss starting at 126 
°C can be observed for all polymer nanocomposite materials and corresponds to the loss of 
unbound water, related to absorbed moisture present in the polymer nanolayer and is due to 
storage under ambient conditions (Figure 2c). The amount of water was determined to be 0.1, 
1.4, and 4.3 wt.% for the Ta2O5-PAA nanocomposite with a polymerization time of 1, 2.5, and 5 
h, respectively.  
For all the PAA-containing materials, three additional mass losses were identified at 253, 295, 
and 530 °C, which is related to the release of organic compounds. The second mass loss can be 
attributed to the formation of PAA anhydride, and the third one corresponds to the degradation of 
the PAA anhydride [40]. The final thermal decomposition of the polymer occurs at a temperature 
above 500 °C [40]. 
The amount of polymer that wraps individual Ta2O5 nanoparticles increases with polymerization 
time, reaching a maximum of 34 wt.% for the nanocomposite sample polymerized during 5 h and 
is in accordance with the increase of the polymer layer thickness, previously observed in figure 
1. 
 
Surface Composition of the Nanomaterials before and after Polymerization: The surface 
composition of the prepared Ta2O5 NPs was evaluated via X-ray photoelectron spectroscopy 
(XPS) and compared to Ta2O5 after additional treatment with HCl to show that the latter sample 
shows surface functionalization with hydroxyl groups, which, in turn, facilitate the 
polymerization of AA onto the NP surfaces.  
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High-resolution XPS survey spectra show typical peaks that can be ascribed to the presence of 
carbon, oxygen, and tantalum (Figure 3, and all XPS data are summarized in Tables S1 and S2 of 
the Supporting Information). The peaks at a lower binding energy of ~285 and ~286 eV can be 
assigned to CH2 and CH, respectively [41]. The peak at ~288 eV is ascribed to C–O bonds, 
which indicates the presence of adventitious carbon. The nanocomposites display an additional 
peak at ~290 eV, which corresponds to the O–C=O groups that are found in PAA [41]. Table 1 
displays the C 1s envelope ratios for all samples and shows, besides the increase in the C/O ratio, 
from ~143% (Ta2O5) to ~218% (Ta2O5-PAA), an increase in the amount of CH bonds that are 
typically found in the polymer chains, underlining the successful polymerization of PAA onto 
the NPs surface. These findings are further supported by the presence of an O 1s peak at ~534 
eV for the O–C=O group, which is only found in the Ta2O5-PAA nanocomposites [41]. 
The O 1s spectra also display peaks that correspond to Ta–O bonds and –OH groups at a binding 
energy of ~531 and 533 eV, respectively [42]. The presence of hydroxyl groups on the surface of 
Ta2O5 after treatment with HCl is of importance, since the –OH groups act as activation sites that 
react with the AA monomers on the NP surfaces to form a layer of PAA, as shown via TEM 






Figure 3. a) XPS survey spectra of Ta2O5 NPs, Ta2O5 NPs after HCl treatment, Ta2O5-PAA 1 h, 
and Ta2O5-PAA 2.5 h. High-resolution spectra of Ta2O5 NPs and Ta2O5 NPs after HCl treatment 
and Ta2O5-PAA nanocomposites with polymerization times of 1 and 2.5 h for b) the C 1s region 
and c) the O 1s region. The spectra have been corrected to C–C at 284.8 eV.   
 
Table 1. XPS analysis including the C 1s region of Ta2O5 NPs (before and after treatment with 
HCl) and Ta2O5-PAA composite nanoparticles. 
Sample XPS C 1s envelope ratios (%) C/O ratio (%) 
CH2 CH C–O O–C=O  
Ta2O5 61.05 25.24 13.71 – 145.38 
Ta2O5 (HCl treated) 55.87 28.51 15.62 – 140.92 
Ta2O5-PAA 1 h 41.70 44.81 9.13 4.36 216.94 
Ta2O5-PAA 2.5 h 40.39 40.40 13.81 5.40 218.17 
 
In Vitro CT Imaging of Ta2O5-PAA Nanocomposites: The anatomical contrast enhancement 
capability of uncoated Ta2O5 NPs and the Ta2O5-PAA nanocomposite with high polymerization 
time (5 h) was demonstrated using a clinical CT scanner, with the resulting CT number as a 
function of the tantalum concentration, as shown in Figure 4. The results of the CT scans of 
uncoated Ta2O5 NPs are shown in Figure S1.  
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The CT values in Hounsfield Units (HU) for each concentration were determined for multiple 
regions along the central axis of the vial to account for possible sedimentation of the suspended 
nanoparticles (see red dashed lines on Figure 4).  
In general, the contrast increased with increasing concentration of tantalum, and the suspension 
remained stable up to a concentration of 8 mg/mL for the Ta2O5-PAA nanocomposite. For the 
uncoated Ta2O5 NPs, however, a noticeable difference in CT number was observed at the highest 
concentration of 8 mg/mL for the center of the composite sediment and the center of the 
suspension height, which ultimately underlines the stabilization effect of PAA on the suspension. 
The data were plotted and fitted to deduce the relationship between the CT number and the 
tantalum concentration. The average CT number was chosen across the suspension height. It 
should be noted that the CT number reached a value of 1000 – 2000 HU in the sediment at a 
tantalum concentration of 8 mg/mL for uncoated Ta2O5, which highlights the potential of Ta2O5 
as an anatomical contrast enhancement agent. These results agree with reported CT numbers for 
Ta-containing compounds and underline the improved suspension stability and reduced beam 
hardening in comparison to previously reported Bi2O3 nanoparticles [3, 43]. 
The PAA layer on the surface of the ceramic particles increased the nanocomposite stability in 
the liquid media, preventing deposition and agglomeration, leading to a superior contrast 
enhancement and contrast-to-noise ratio of Ta2O5-PAA for high X-ray energies are of particular 
interest in a clinical setup [44]. Although it is beneficial for pediatric patients to reduce the 
radiation dose, the ability to use high X-ray energies is important for the imaging of large 




Figure 4. a) CT images of Ta2O5-PAA NPs (5h polymerization) with Ta mass concentrations of 
0 – 8 mg/mL; the red dashed line indicates the area which was used to determine the CT number 
(suspension height and sediment). The tube potential varied between 100, 120, and 135 kVp and 
b) Linear fitting of the CT number of Ta2O5-PAA NPs (5h polymerization) as a function of the 
mass concentration of Ta in mg/mL at different tube potentials of 100, 120, and 135 kVp. The 
equation of the linear regression and the R2 value are indicated. 
 
Swelling and MTX Capacity of Ta2O5-PAA Nanocomposites: Investigation of the swelling 
behavior of PAA-containing nanomaterials is of importance since the swelling property 
influences the diffusion of small molecules through the polymer matrix. PAA is a hydrogel and 
increasing its content leads to larger water affinity, which ultimately results in higher swelling 
ratios (SR) [45]. 
The swelling kinetics of the Ta2O5 NPs and the Ta2O5-PAA nanocomposites for a time frame of 
0 – 48 h at 37 °C and pH 7.4 are displayed in Figure 5a. As the thickness of the PAA layer 
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increases, the volume of the hydrogel also increases, and consequently the swelling ratio. In 
general, the swelling ratio increases rapidly in the first 4 h and reaches equilibrium after around 




Figure 5. a) Swelling ratio of Ta2O5 NPs and Ta2O5-PAA nanocomposites with polymerization 
times of 1, 2.5, and 5 h. The swelling properties were measured at 37 ºC, at pH 7.4 for 48 h, b) 
The influence of the pH value of the buffer solution on the swelling ratio of the Ta2O5-PAA 
nanocomposite that was synthesized with a polymerization time of 5 h. The swelling properties 
were measured at 37 ºC, at pH 3.6, 5.4, 7.4, and 9.4 for 48 h, c) The absorbance of MTX solution 
at concentrations ranging from 2.5 – 45 µM, d) Calibration curve and the equation for the 
calculation of MTX concentration. In vitro release profiles of e) MTX-soaked Ta2O5 NPs and 
Ta2O5-PAA nanocomposites with different polymerization times of 1, 2.5, and 5 h in a buffer 
solution with pH 7.4, and f) Ta2O5-PAA with longest polymerization time of 5 h in buffer 
solutions with pH values of 3.6, 5.4, 7.4, and 9.4. The drug release was monitored at 37 ºC for 72 
h.  
 
To study the effect of pH on the swelling ratio, we chose the nanocomposite with the highest 
amount of PAA (Ta2O5-PAA 5 h) and exposed it to buffer solutions with different pH (pH 3.6, 
5.4, 7.4, and 9.4) at 37 ºC (Figure 5b).  
The difference in swelling ratio is ascribed to the accessibility of free volume for the expanded 
polymer matrix, the polymer chain relaxation, and the availability of ionizable functional groups 
[45]. For instance, the presence of carboxyl groups can lead to the formation of hydrogen bonds 
with water. In addition, the swelling behavior depends on the network swelling pressure, the 
dissociation equilibrium and the presence of ions and impurities in the swelling medium [46].  
The carboxylic acid group in PAA tends to dissociate at pH values greater than 4.5, which 
ultimately leads to an increase in osmotic pressure inside the polymer matrix and explains the 
low swelling ratio in the buffer solution of pH 3.6 [45]. With increasing pH, the dissociation of 
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carboxylic groups increases, which leads to negatively charged polymer chains that repel each 
other[45], creating more free space between the polymer chains, ultimately leading to an increase 
in the swelling ratio.  
When the hydrogel is placed into the aqueous solution containing MTX, the polymer network 
starts to swell, and the drug molecules will penetrate and fill the space between the polymer 
chains. The thicker the polymer layer, the larger is the swelling ratio (Figure 5a). The MTX 
molecules and PAA chains experience electrostatic repulsion at a pH of 7.4, which could explain 
the low increase in loading capacity for the nanocomposite with thickest polymer layer [29, 31, 
47]. The effects are described in more detail in the next section (Figure 6).  
The MTX entrapment per 1 mg of the nanocomposite was also determined via UV-vis 
spectroscopy after the in vitro drug release experiments and the treatment of the composites with 
0.1 M NaOH. The calibration curve of different concentrations of MTX was determined and is 
shown in Figures 5c and 5d. The MTX entrapment obtained via UV-vis spectroscopy 
corroborates the value calculated through the dry weight of the composite after the drug loading 









Table 2. Loading capacity (LC) and entrapment efficiency (EE) of Ta2O5 NPs and Ta2O5-PAA 
composite nanoparticles with different polymerization times at a weight ratio of MTX/composite 
of 1/1 (10 mg/mL).  
Sample MTX/ 1 mg 
composite (dry 
weight) [µg] 









MTX/ 1 mg 
composite 
(UV-vis) [µg] 
Ta2O5 11.5 ± 0.7 1.2 ± 0.1 -  8.3 ± 1.31 
Ta2O5-PAA 1 h 21.3 ± 2.5 2.1 ± 0.3 95.5 ± 11.2 20.2 + 2.9 
Ta2O5-PAA 2.5 
h 
76.6 ± 9.3 7.7 ± 0.9 75.7 ± 9.2 67.5 ± 5.6 
Ta2O5-PAA 5 h 126.4 ± 8.7 12.6 ± 0.9 31.6 ± 2.2 118.0 ± 4.1 
a Normalized to the mass of composite. 
b Normalized to the mass of PAA. 
 
The reported drug loading capacities for similar systems range from 12 – 80%, based on the 
delivery system components, the drug entrapment method, the incubation time, and the drug 
concentration used for the entrapment [29, 31, 48, 49]. For instance, it was shown for DOX as a 
model drug and a system consisting of mesoporous silica and PAA, that by increasing the weight 
ratio of drug/hydrogel from 0.1 to 1.0, the loading capacity increased from 2.2 to 40.2% [30], 
and with an entrapment efficiency that ranges from 25.1 to 80.4%, respectively [30].  
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Ta2O5-PAA nanocomposites showed an entrapment efficiency up to 95% for the sample with the 
thin PAA layer, down to 32% for the sample with 8.2 ± 1.4 nm polymer layer surrounding the 
ceramic particle (table 2). 
  
Effect of PAA Layer Thickness on the Release of MTX from Ta2O5-PAA Nanocomposites: Drug 
release kinetics, measured at different pHs’s and for the samples with different polymer shell 
thickness was studied according to the mathematical model developed by Ritger-Peppas: 
;<
;=
= >?@   (6) 
where M∞ is the total amount of drug, Mt is the amount of drug released at time t, k is a kinetic 
constant, and n is the diffusion exponent. For modeling, only fractions < 0.6 were considered. 
It was observed that for all tested samples, a burst release of MTX occurred in the first hour, 
which is due to desorption of MTX from the gel surface. The following release of the drug was 
slower and after 72 h, it yielded a total release of MTX of 100% for the Ta2O5 NPs, and 86, 89, 
and 92% for the Ta2O5-PAA nanocomposites with a polymerization time of 1, 2, and 5 h, 
respectively. The fast release of MTX from the uncoated Ta2O5 NPs is related to the absence of a 
protective hydrogel shell that creates a physical barrier, delaying the release. 
When the MTX-loaded hydrogel is placed in the release medium, the polymer starts to swell, 
followed by polymer chain relaxation and volume expansion. This enables the trapped MTX to 
diffuse into the external release medium [47]. The observed release rate tends to increase with 




The drug release kinetics of Ta2O5 NPs was impossible to determine due to the boost of drug 
release to the buffer solution that started immediately after immersion of the particles in the 
media. A value for n between 0.54 and 0.71 was obtained for all the nanocomposites and 
indicates that the drug transport mechanism appears to be anomalous: the drug release is 
controlled by a coupled effect of Fickian diffusion and chain relaxation of the hydrogels (Table 
3). 
Table 3. Ritger-Peppas fitting parameters obtained for Ta2O5-PAA composite nanoparticles with 
different polymerization times. 
Sample k n R
2
 Transport mechanism 
Ta2O5-PAA 1 h 1.54 ± 0.01  0.54 ± 0.03 0.990 Diffusion and relaxation controlled 
Ta2O5-PAA 2.5 
h 
1.60 ± 0.01 0.61 ± 0.03 0.992 Diffusion and relaxation controlled 
Ta2O5-PAA 5 h 1.78 ± 0.02 0.71 ± 0.05 0.987 Diffusion and relaxation controlled 
 
 
Effect of pH on the Drug Release Kinetics: To evaluate the effects of pH on the overall drug 
release and its mechanism, the Ta2O5-PAA (5 h polymerization time) soaked with MTX was 
placed in the release buffers with pH of 3.6, 5.4, 7.4, and 9.4 (Figure 5f). The drug release from 
the nanocomposites follows a similar profile for all tested pH values, starting with the initial 
burst release of MTX, which is followed by the slow release at longer incubation times. While 
the total release of MTX is only 79% at a pH of 3.6, the drug release increases to 84, 92, and 
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96% for pH of 5.4, 7.4, and 9.4, respectively. Moreover, the initial burst release of MTX was 
significantly reduced for the lowest pH of 3.6, showing that the swelling of the PAA nanolayer is 
the principal parameter ruling drug release (Figure 5b). Since the swelling ratio increases with 
increasing pH of the buffer solution and entraps more drug into the polymer network, and 
consequently more drug can be released from the hydrogel as the structure becomes more open 
[47]. 
The analysis of the drug release kinetics indicates that the release mechanism strongly depends 
on the pH of the release medium [27, 45, 47]. The diffusion exponent n increased as the pH of 
the release medium became more alkaline, which underlines the pH sensitivity of PAA-
containing hydrogels (Table 4). For a pH of 3.6, the release followed Fickian diffusion (n < 0.5). 
With regard to the release of MTX, Fick’s law includes the adsorption of buffer on the polymer 
matrix and the simultaneous desorption of MTX via diffusion [27]. For pH values of 5.4 and 7.4, 
the increase in the diffusion coefficient (n = 0.54 ± 0.03 to 0.71 ± 0.05) suggesting that the 
release mechanism is a result of the contributions of both Fickian diffusion and relaxation of 
polymer chains. At a pH of 9.4, the extensive ionization of the functional groups significantly 
influences the polymer chain relaxation and consequently, leads to a transport mechanism that is 








Table 4.  Ritger-Peppas fitting parameters obtained for theTa2O5-PAA composite nanoparticles 
with 5 h polymerization time, exposed to different pH environments. 
Sample k n R
2
 Transport mechanism 
pH 3.6 1.39 ± 0.01 0.28 ± 0.03 0.966 Diffusion controlled 
pH 5.4 1.61 ± 0.01 0.54 ± 0.03 0.992 Diffusion and relaxation controlled 
pH 7.4 1.78 ± 0.02 0.71 ± 0.05 0.987 Diffusion and relaxation controlled 
pH 9.4 1.88 ± 0.01 0.84 ± 0.01 0.999 Relaxation controlled 
  
In addition to the effect of the swelling ratio, the presence of electrostatic interactions between 
the drug and the hydrogel can also influence the drug release [29, 31, 47], as schematically 
shown in Figure 6. MTX has three pKa values at 3.8, 4.8, and 5.6, while the dissociation of the 
carboxylic group of PAA takes place at pKa of 4.25 [50]. At pH 3.6, the nitrogen atom in the 
pteridine ring should be mainly protonated, while the carboxylic groups on the hydrogel are 
hardly ionized. This leads to the presence of weak hydrogen bonding between the carboxylic 
groups of MTX and PAA. At pH 5.4, the carboxylic groups on the PAA chains are partly 
deprotonated and form carboxylate anions, which leads to fewer hydrogen bonds. Moreover, the 
carboxylic groups of the MTX molecule start to dissociate, which causes further negative charge 
and consequently, increases the electrostatic repulsion between the MTX molecule and the PAA 
chains. 
At pH of 7.4 and 9.4, the nitrogen atom of the pteridine ring is mostly deprotonated, which 
further increases the electrostatic repulsion between the MTX molecule and the PAA. The 
increase in pH shifts the equilibrium further to dissociated components and increases the 
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electrostatic repulsion and the release of MTX. Moreover, the solubility of PAA increases with 
increasing pH, which can lead to the degradation and erosion of the polymer matrix and thus, to 
the increased release of entrapped MTX, especially for long incubation times [51, 52].  
 
Figure 6. a) Structure of MTX, and b) Schematic route of the MTX loading and release from the 
nanocomposites containing PAA at different pH values (3.6, 5.4, 7.4, and 9.4). 
 
CONCLUSIONS 
To design a theranostic system with controlled drug release properties, Ta2O5-PAA 
nanocomposites were prepared through the polymerization of AA on the surfaces of individual 
Ta2O5 NPs. By varying the polymerization time, different layer thicknesses of PAA on the 
surfaces of the ceramic particles were obtained, which ultimately had an impact on the drug 
loading capacity.  
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MTX-loaded Ta2O5-PAA matrices were prepared by soaking Ta2O5-PAA in a solution of MTX, 
and the release mechanism was studied by the Ritger-Peppas model. It was demonstrated that the 
Ta2O5-PAA nanocomposites were highly sensitive to different pH environments. Firstly, the 
swelling ratio increased with increasing pH of the swelling medium. Secondly, an acidic release 
medium slowed down the release of MTX, while more alkaline pH values led to a quick release 
of MTX from the MTX-loaded Ta2O5-PAA matrices. The diffusion exponent n increased from 
0.28 to 0.84, which suggests that, with increasing pH, polymer chain relaxation contributes to the 
transport mechanism. These results indicate that such a system may, under certain conditions, 
provide release characteristics approaching zero-order release.  
Furthermore, the Ta2O5-PAA nanocomposites showed a contrast enhancement for tube potentials 
ranging from 100 – 135 kVp in vitro. The image consistency at high X-ray energies is of interest 
in a clinical setup, as it ensures enough penetration of X-rays in larger patients.  
The results evidence that Ta2O5-PAA nanocomposites can be successfully used as drug delivery 
systems, providing imaging, therapeutic, targeting, and potentially, radiation dose enhancement 
functionalities on one single platform.  
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